Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can genetic testing help men with metastatic prostate cancer?

NCT ID NCT03503097

Knowledge-focused Sponsor: University of Washington Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study offered genetic testing to men whose prostate cancer has spread to other parts of the body. Participants provided saliva samples to check for inherited mutations in about 30 cancer-risk genes. The goal was to understand how often these mutations occur and how men feel about genetic testing. The study did not provide treatment, but shared results with participants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could show that offering genetic testing to men with metastatic prostate cancer is acceptable and useful for identifying inherited cancer risks.
What could go wrong
This study was terminated early, so results may be incomplete. It is an observational study, not a treatment trial, so no direct health benefit is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

799 people

The number who actually took part.

Started

Aug 2017

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with metastatic prostate cancer

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent form (ICF) providing agreement for germline genetic testing, use and release of health and research trial information * Documented evidence of metastatic prostate cancer; * Oncologist note within 4 months * All computed tomography (CT), bone, positron emission tomography (PET) scan reports within 12 months * All prostate-specific antigen (PSA) values within 12 months * All available pathology reports from diagnosis, prostatectomy, and/or metastatic biopsy * Willingness to provide basic demographic information, family cancer history, and treatment history * Willingness and ability to complete patient reported outcomes questionnaire (on-line or hard copy) at enrollment, and at 6-month follow-up * Willingness and ability to provide saliva sample Exclusion Criteria: * Unable or unwilling to provide all of the necessary information for eligibility, e.g. decisionally impaired * Incomplete inclusion criteria * Study team members

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic prostate carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma Neoplasm Metastasis prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic prostate carcinoma Stage IV prostate cancer ajcc V8 Stage IVB prostate cancer ajcc V8

Contacts and locations

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.